<
https://www.news-medical.net/news/20260630/Review-highlights-strong-safety-and-effectiveness-of-mRNA-vaccines.aspx>
"A comprehensive new review published in
The Lancet affirms that currently
approved mRNA vaccines are safe and highly effective at preventing infectious
diseases, including COVID-19. The new review also suggests that mRNA vaccine
technologies have potential as new options for treating and preventing other
health conditions and diseases, including influenza, RSV, cancer, and
autoimmune conditions.
Through detailed analysis of published data from laboratory research, clinical
trials, and real-world surveillance of billions of mRNA vaccine doses, the
authors assessed the science behind mRNA vaccines and their public health
impact.
The review concludes that serious adverse side effects from mRNA vaccines
remain exceedingly rare. For example, in real world surveillance, incidents of
myocarditis and pericarditis (heart-related inflammation) following vaccination
were higher among second-dose recipients, with rates of roughly 12.6 cases per
million for Pfizer BioNTech's BNT162b2 vaccine and about 35.6 cases per million
for Moderna's mRNA-1273. Importantly, the increased risk of myocarditis and
pericarditis from mRNA COVID-19 vaccines, particularly in males aged 12-19, was
significantly lower than the risk of developing myocarditis or pericarditis
from a SARS-CoV-2 infection. Other serious adverse events were also very rare.
For example, the risk of anaphylaxis was 4.7 cases per million doses (Pfizer),
and Guilain Barre Syndrome was 38 cases per million doses (AstraZeneca). Most
other side effects, such as sore arms, fatigue, or fever, were mild to moderate
and subsided after a few days.
The analysis found that across various clinical trials and real-world data,
mRNA vaccines are about 87% effective against any documented SARS‑CoV‑2
infection, 93% effective against hospitalization, and 94% effective against
mortality within 14–42 days after vaccination. Effectiveness waned over time
and, in some analyses, was reduced by age and against the Omicron lineage (67%
against infection and 72% against hospitalization), but booster doses helped
restore protection. Ongoing surveillance and real‑world monitoring continue to
support the vaccines' tolerability and effectiveness as new variants emerge,
and booster programs are implemented to maintain protection."
Via Violet Blue’s
Threat Model - Pandemic Roundup: July 2, 2026
https://www.patreon.com/violetblue/posts/pandemic-roundup-162676753
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
